NovAb
NovAb develops and commercializes monoclonal antibody technology based on variable lymphocyte receptors (VLRs), antigen receptors from jawless vertebrates. The company focuses on discovery and engineering of small, single-polypeptide VLR antibodies with glycan-targeting specificities, multivalent ligand scaffolds for receptor/cell targeting and delivery, and VLR-based reagents and therapeutic formats (including VLR-Ig chimeras and multivalent polymers).
Industries
Nr. of Employees
small (1-50)
Products
Variable Lymphocyte Receptors (VLRs)
A new class of monoclonal antibodies from jawless vertebrates composed of tandemly linked leucine-rich repeat domains, distinct from conventional immunoglobulins, enabling novel antigen specificities and multivalent antibody polymers.
VLR-Ig Chimeras
Therapeutic monoclonal antibodies created by replacing Ig variable regions with VLR sequences, combining novel antigen recognition with Ig effector functions and pharmacokinetics.
Variable Lymphocyte Receptors (VLRs)
A new class of monoclonal antibodies from jawless vertebrates composed of tandemly linked leucine-rich repeat domains, distinct from conventional immunoglobulins, enabling novel antigen specificities and multivalent antibody polymers.
VLR-Ig Chimeras
Therapeutic monoclonal antibodies created by replacing Ig variable regions with VLR sequences, combining novel antigen recognition with Ig effector functions and pharmacokinetics.
Services
Collaborative discovery and engineering services for VLR monoclonal antibodies including lamprey immunization, library construction, selection, sequencing, and provision of reagents and protocols; available via technology transfer or licensing arrangements.
Collaborative construction and transfer of multimeric ligand compositions (scaffolds with multiple attached ligands) to support partner R&D including receptor identification, cell targeting, and delivery approaches.
Collaborative discovery and engineering services for VLR monoclonal antibodies including lamprey immunization, library construction, selection, sequencing, and provision of reagents and protocols; available via technology transfer or licensing arrangements.
Collaborative construction and transfer of multimeric ligand compositions (scaffolds with multiple attached ligands) to support partner R&D including receptor identification, cell targeting, and delivery approaches.
Expertise Areas
- Monoclonal antibody discovery (non-Ig antigen receptors)
- Glycobiology and glycan-specific reagent development
- Antibody engineering (multispecifics, bispecifics, polymers)
- Multivalent ligand platforms and targeted delivery
Key Technologies
- Leucine-rich repeat (LRR)-based antigen receptors (VLRs)
- Yeast display library construction and selection
- Multimeric ligand scaffolds
- Antibody Fc-fusion expression and characterization
News & Updates
Lecture delivered by Max Cooper at the annual meeting of the AAP/ASCI/APSA.
Coverage noting the 2019 Albert Lasker Basic Medical Research Award honoring Max D. Cooper and Jacques Miller.
Nature article featuring work on glycan analysis and the discoveries underpinning NovAb's approach.
Article describing lampreys as a model for alternative adaptive immunity and related research.
Max D. Cooper recognized with the Lasker Prize for discoveries in B and T lymphocyte lineages.
Max D. Cooper named 2018 Japan Prize Laureate for discovery of B and T lymphocyte lineages.
Lecture delivered by Max Cooper at the annual meeting of the AAP/ASCI/APSA.
Coverage noting the 2019 Albert Lasker Basic Medical Research Award honoring Max D. Cooper and Jacques Miller.
Nature article featuring work on glycan analysis and the discoveries underpinning NovAb's approach.
Article describing lampreys as a model for alternative adaptive immunity and related research.
Max D. Cooper recognized with the Lasker Prize for discoveries in B and T lymphocyte lineages.
Max D. Cooper named 2018 Japan Prize Laureate for discovery of B and T lymphocyte lineages.